JP6726658B2 - ヒストン脱アセチル化酵素阻害剤 - Google Patents
ヒストン脱アセチル化酵素阻害剤 Download PDFInfo
- Publication number
- JP6726658B2 JP6726658B2 JP2017504608A JP2017504608A JP6726658B2 JP 6726658 B2 JP6726658 B2 JP 6726658B2 JP 2017504608 A JP2017504608 A JP 2017504608A JP 2017504608 A JP2017504608 A JP 2017504608A JP 6726658 B2 JP6726658 B2 JP 6726658B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- stirred
- nmr
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1/C2=C/C=C/C=C/C=C2/N(*)*1* Chemical compound *C1/C2=C/C=C/C=C/C=C2/N(*)*1* 0.000 description 4
- SREUIOCQUYDLGT-CMDGGOBGSA-N CC(C)(C)OC(/C=C/c(cc1cc2)cnc1[n]2S(c1cc(OC)ccc1)(=O)=O)=O Chemical compound CC(C)(C)OC(/C=C/c(cc1cc2)cnc1[n]2S(c1cc(OC)ccc1)(=O)=O)=O SREUIOCQUYDLGT-CMDGGOBGSA-N 0.000 description 1
- MPXAYYWSDIKNTP-UHFFFAOYSA-N CC(Nc1ccccc1N)=O Chemical compound CC(Nc1ccccc1N)=O MPXAYYWSDIKNTP-UHFFFAOYSA-N 0.000 description 1
- ZSZKTRZRZUZMFL-UHFFFAOYSA-N O=S(c(cc1)ccc1F)(N(CC1)c(nc2)c1cc2Br)=O Chemical compound O=S(c(cc1)ccc1F)(N(CC1)c(nc2)c1cc2Br)=O ZSZKTRZRZUZMFL-UHFFFAOYSA-N 0.000 description 1
- FOSVQPBNTMECKX-UHFFFAOYSA-N O=S(c1cccc(Br)c1)([n](ccc1c2)c1ncc2Br)=O Chemical compound O=S(c1cccc(Br)c1)([n](ccc1c2)c1ncc2Br)=O FOSVQPBNTMECKX-UHFFFAOYSA-N 0.000 description 1
- ULTGDYNONJUSLN-SNAWJCMRSA-N OC(/C=C/c1cc(CCN2S(c3cc(Cl)ccc3)(=O)=O)c2nc1)=O Chemical compound OC(/C=C/c1cc(CCN2S(c3cc(Cl)ccc3)(=O)=O)c2nc1)=O ULTGDYNONJUSLN-SNAWJCMRSA-N 0.000 description 1
- IHVNRPKEWZQSTQ-KQQUZDAGSA-N OC(/C=C/c1cc(CCN2S(c3ccccc3/C=C/C(O)=O)=O)c2nc1)=O Chemical compound OC(/C=C/c1cc(CCN2S(c3ccccc3/C=C/C(O)=O)=O)c2nc1)=O IHVNRPKEWZQSTQ-KQQUZDAGSA-N 0.000 description 1
- LGQWBBXWMKZGOQ-LZCJLJQNSA-N [O-][N+](c(cc1)ccc1S(N1c2ncc(/C=C/C(NO)=O)cc2CC1)(=O)=O)=O Chemical compound [O-][N+](c(cc1)ccc1S(N1c2ncc(/C=C/C(NO)=O)cc2CC1)(=O)=O)=O LGQWBBXWMKZGOQ-LZCJLJQNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978606P | 2014-04-11 | 2014-04-11 | |
| US61/978,606 | 2014-04-11 | ||
| PCT/US2015/025084 WO2015157504A1 (en) | 2014-04-11 | 2015-04-09 | Histone deacetylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510660A JP2017510660A (ja) | 2017-04-13 |
| JP2017510660A5 JP2017510660A5 (https=) | 2018-05-31 |
| JP6726658B2 true JP6726658B2 (ja) | 2020-07-22 |
Family
ID=54288395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504608A Active JP6726658B2 (ja) | 2014-04-11 | 2015-04-09 | ヒストン脱アセチル化酵素阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10246455B2 (https=) |
| EP (1) | EP3129373B1 (https=) |
| JP (1) | JP6726658B2 (https=) |
| CN (1) | CN107001354B (https=) |
| TW (1) | TWI573787B (https=) |
| WO (1) | WO2015157504A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745253B2 (en) | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
| EP3313399A4 (en) * | 2015-06-29 | 2019-07-24 | NantBio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING RIT1 |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CN105622605B (zh) * | 2016-03-01 | 2017-10-13 | 苏州艾缇克药物化学有限公司 | 一种5‑溴‑7‑氮杂吲哚的合成方法 |
| TWI659949B (zh) * | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| CN107011238B (zh) * | 2017-03-14 | 2020-05-01 | 北京化工大学 | 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途 |
| WO2018200608A1 (en) * | 2017-04-26 | 2018-11-01 | The Board Of Trustees Of The University Of Illinois | Nrf and hif activators/hdac inhibitors and therapeutic methods using the same |
| CN109705015B (zh) * | 2017-10-25 | 2022-05-24 | 成都先导药物开发股份有限公司 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
| CN108794469A (zh) * | 2018-04-28 | 2018-11-13 | 通化师范学院 | 一种吡咯化合物的合成新工艺及抗肿瘤作用的用途 |
| US11554120B2 (en) * | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN115636774B (zh) * | 2022-12-01 | 2023-12-22 | 南开大学 | 一种贝利司他的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4288595A (en) * | 1980-04-24 | 1981-09-08 | American Home Products Corporation | 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines |
| GB0305142D0 (en) * | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| AU2004262976A1 (en) | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| GB0318254D0 (en) * | 2003-08-04 | 2003-09-10 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| ES2736200T3 (es) * | 2009-07-22 | 2019-12-26 | Univ Illinois | Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
| WO2011019634A2 (en) * | 2009-08-10 | 2011-02-17 | Taipei Medical University | Aryl substituted sulfonamide compounds and their use as anticancer agents |
| RU2711869C3 (ru) * | 2009-12-01 | 2022-02-02 | Эббви Инк. | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
| CA2787784A1 (en) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| TWI429628B (zh) * | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| AU2012212323A1 (en) * | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| CN103906732A (zh) * | 2011-10-28 | 2014-07-02 | 株式会社钟根堂 | 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物 |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
-
2015
- 2015-04-09 CN CN201580019257.4A patent/CN107001354B/zh active Active
- 2015-04-09 US US15/302,739 patent/US10246455B2/en active Active
- 2015-04-09 WO PCT/US2015/025084 patent/WO2015157504A1/en not_active Ceased
- 2015-04-09 EP EP15776965.4A patent/EP3129373B1/en active Active
- 2015-04-09 JP JP2017504608A patent/JP6726658B2/ja active Active
- 2015-04-13 TW TW104111835A patent/TWI573787B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201609642A (zh) | 2016-03-16 |
| CN107001354B (zh) | 2021-06-22 |
| EP3129373A4 (en) | 2017-11-29 |
| WO2015157504A1 (en) | 2015-10-15 |
| JP2017510660A (ja) | 2017-04-13 |
| EP3129373B1 (en) | 2021-09-01 |
| EP3129373A1 (en) | 2017-02-15 |
| TWI573787B (zh) | 2017-03-11 |
| US20170057956A1 (en) | 2017-03-02 |
| US10246455B2 (en) | 2019-04-02 |
| CN107001354A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6726658B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
| AU2011238628B2 (en) | Indolyl or indolinyl hydroxamate compounds | |
| JP2021512166A (ja) | 化合物及びその使用 | |
| CA3119526A1 (en) | Small molecule degraders of helios and methods of use | |
| AU2018300123B2 (en) | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) | |
| JP2005510517A5 (ja) | シクロオキシゲナーゼ−２インヒビター／ヒストン・デアセチラーゼ・インヒビター組合せ剤 | |
| WO2016166250A1 (en) | Quinoline derivatives as tam rtk inhibitors | |
| JP6615207B2 (ja) | 複素環式化合物及びその使用 | |
| CN105722840B (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| CA2973773C (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| CN108366979B (zh) | 与泛素化－蛋白酶体系统有关的化合物及医药组合物 | |
| JP2020512327A (ja) | 熱ショックタンパク質９０阻害剤 | |
| CN114302874B (zh) | 吲哚甲酰胺衍生物和包含吲哚甲酰胺衍生物的药物组合物 | |
| CN107793360B (zh) | 吲哚胺2,3-双加氧酶抑制剂与应用 | |
| AU2021265994B2 (en) | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | |
| TWI684581B (zh) | 與泛素化-蛋白酶體系統有關之化合物及醫藥組合物 | |
| CA3069273C (en) | Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2 (hdac1-2) | |
| CN112062717A (zh) | 一种吲哚胺2,3-双加氧酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190917 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200602 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200629 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6726658 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |